GE HealthCare Share Price at $74: Why the Quiet Medtech Giant Is Back on Buy Lists

There’s a glass-walled office building on Chicago’s Near North Side where, if you stand on the right corner of North LaSalle Street at about 8:45 a.m., you can watch a particular kind of commuter walk in — imaging scientists, radiology software engineers, clinical product managers, people whose work ultimately ends up inside an MRI scanner at a community hospital in Ohio or a breast cancer screening clinic in Manchester. Three years after splitting off from General Electric, GE HealthCare has quietly become one of the more interesting medtech companies in the United States. Its stock hasn’t quite figured that out yet.

Shares closed Monday at $74.15, down 0.68% on the day, with pre-market trading flat into Tuesday. The market cap sits at about $33.83 billion. Year-to-date, GEHC is down roughly 9.9% — an unusual position for a medical-technology name with strong earnings momentum and a growing AI franchise. Over the trailing twelve months, though, the stock is up about 20%, which tells you something about how volatile this corner of the market has been. Investors have been trying to price GEHC as either a growth-medtech story like Intuitive Surgical or a slow-compounder like Siemens Healthineers, and the truth is probably somewhere uncomfortably in between.

The business underneath is genuinely solid. 2024 revenue came in at about $19.7 billion. Fourth-quarter 2025 revenue hit $5.7 billion, up 7.13% year-over-year, with both EPS and the top line beating analyst estimates. The company’s product mix — MRI and CT imaging, ultrasound, patient monitoring, and pharmaceutical diagnostics — is the kind of diversified medtech portfolio that doesn’t live or die on any single quarter. Hospitals don’t switch imaging vendors the way they switch IT software. Once a radiology department is equipped with a GE Signa MRI or a Revolution CT, the switching cost is measured in years and millions of dollars. That’s a moat, even if it’s a boring one.

What’s been changing, and what the market seems to be slowly waking up to, is GE HealthCare’s push into clinical AI. Last week, the company expanded its mammography partnership with DeepHealth, RadNet’s AI subsidiary, integrating automated breast density assessment, workflow triage, and cancer-detection algorithms directly into GE’s screening systems. The deal extends well beyond the U.S., targeting international breast cancer programs across the UK, Canada, Australia, and parts of Europe. It’s not the kind of headline that moves a stock 10% in a day, but it’s the kind of headline that adds up, slowly, in software and services revenue — the highest-margin parts of any medical device business.

Valuation is where the argument gets genuinely interesting. Simply Wall St. ran a 2-stage DCF on the name last week and produced an intrinsic value of $110.82 per share, a 32.6% discount to the current price. The platform’s value score on GEHC is 6 out of 6, with all six of their valuation checks flagging the stock as undervalued. The sell-side consensus is more measured — a 1-year target of about $90.74 — but even that implies roughly 22% upside. The stock trades at a 16.30 P/E versus 26 for the broader Medical Equipment industry and around 34 for its closest peer group. Either the market sees a problem that hasn’t shown up in the numbers, or it’s simply mispricing a spun-off subsidiary the way it often does in the first few years after a separation.

There are risks, to be fair. Regulatory concerns around AI-driven diagnostics are real, particularly in Europe where the AI Act’s implementation for medical devices creates fresh compliance burdens. Tariff exposure on imported components remains a question for any company that manufactures imaging hardware across multiple geographies. And hospital capital spending cycles are never fully predictable — a tight budget year at major U.S. health systems could soften the equipment order book for a quarter or two. Analysts at Simply Wall St. flagged these specifically as the kind of near-term drag that could justify the more conservative $75 low target.

Still, there’s a sense that GE HealthCare is reaching the point in its standalone life where investors start treating it as its own company rather than a footnote in the General Electric breakup. The Q1 earnings report on April 29 will be a genuine test. If margins hold, if the software and services line continues expanding, and if management guides confidently into the second half, the current $74 print will look, in retrospect, like one of those quiet entry points that everyone claims to have seen coming. Watching this unfold, there’s a feeling that the stock’s 2026 correction has less to do with the business itself and more to do with investor fatigue after three years of spinoff storytelling. That fatigue usually clears. Usually. And when it does, GEHC tends to be the kind of name that rewards patience more than timing.